Association between Fibroblast Growth Factor 19 and Depressive Symptoms: The Moderating Role of Smoking.

IF 2.6 4区医学 Q3 NEUROSCIENCES

Acta Neuropsychiatrica Pub Date : 2025-07-14 DOI:10.1017/neu.2025.10028

Siyuan Li, Lingling Chen, Mingwei Ma, Yueling Hu, Fan Wang, Xingguang Luo, Yu-Hsin Chen, Hongke Gao, Yulin Ren, Weiming Hu, Yimin Kang, Wei Wang, Li Chen, Xiaokun Li, Yanlong Liu, Junnan Wu

{"title":"Association between Fibroblast Growth Factor 19 and Depressive Symptoms: The Moderating Role of Smoking.","authors":"Siyuan Li, Lingling Chen, Mingwei Ma, Yueling Hu, Fan Wang, Xingguang Luo, Yu-Hsin Chen, Hongke Gao, Yulin Ren, Weiming Hu, Yimin Kang, Wei Wang, Li Chen, Xiaokun Li, Yanlong Liu, Junnan Wu","doi":"10.1017/neu.2025.10028","DOIUrl":null,"url":null,"abstract":"Objective: This study aimed to examine the relationship between FGF19 and depressive symptoms, measured by BDI scores and investigate the moderating role of smoking.Methods: This study involved 156 Chinese adult males (78 smokers and 78 non-smokers) from September 2014 to January 2016. The severity of depressive symptoms was evaluated using the BDI scores. Spearman rank correlation analyses were used to investigate the relationship between CSF FGF19 levels and BDI scores. Additionally, moderation and simple slope analyses were applied to assess the moderating effect of smoking on the relationship between the two.Results: FGF19 levels were significantly associated with BDI scores across all participants (r = 0.26, p < 0.001). Smokers had higher CSF FGF19 levels and BDI scores compared to non-smokers (445.9 ± 272.7 pg/ml vs 229.6 ± 162.7 pg/ml, p < 0.001; 2.7 ± 3.0 vs 1.3 ± 2.4, p < 0.001). CSF FGF19 levels were positively associated with BDI scores in non-smokers (r = 0.27, p = 0.015), but no similar association was found among smokers (r = -0.11, p = 0.32). Linear regression revealed a positive correlation between FGF19 and BDI scores (β = 0.173, t = 2.161, 95% CI: 0.015- 0.331, p < 0.05), which was negatively impacted by smoking (β = -0.873, t = -4.644, 95% CI: -1.244 to -0.501, p < 0.001).Conclusion: These results highlight the potential role of FGF19 in individuals at risk for presence of or further development of depressive symptoms and underscore the importance of considering smoking status when examining this association.","PeriodicalId":48964,"journal":{"name":"Acta Neuropsychiatrica","volume":" ","pages":"1-25"},"PeriodicalIF":2.6000,"publicationDate":"2025-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta Neuropsychiatrica","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1017/neu.2025.10028","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"NEUROSCIENCES","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: This study aimed to examine the relationship between FGF19 and depressive symptoms, measured by BDI scores and investigate the moderating role of smoking.

Methods: This study involved 156 Chinese adult males (78 smokers and 78 non-smokers) from September 2014 to January 2016. The severity of depressive symptoms was evaluated using the BDI scores. Spearman rank correlation analyses were used to investigate the relationship between CSF FGF19 levels and BDI scores. Additionally, moderation and simple slope analyses were applied to assess the moderating effect of smoking on the relationship between the two.

Results: FGF19 levels were significantly associated with BDI scores across all participants (r = 0.26, p < 0.001). Smokers had higher CSF FGF19 levels and BDI scores compared to non-smokers (445.9 ± 272.7 pg/ml vs 229.6 ± 162.7 pg/ml, p < 0.001; 2.7 ± 3.0 vs 1.3 ± 2.4, p < 0.001). CSF FGF19 levels were positively associated with BDI scores in non-smokers (r = 0.27, p = 0.015), but no similar association was found among smokers (r = -0.11, p = 0.32). Linear regression revealed a positive correlation between FGF19 and BDI scores (β = 0.173, t = 2.161, 95% CI: 0.015- 0.331, p < 0.05), which was negatively impacted by smoking (β = -0.873, t = -4.644, 95% CI: -1.244 to -0.501, p < 0.001).

Conclusion: These results highlight the potential role of FGF19 in individuals at risk for presence of or further development of depressive symptoms and underscore the importance of considering smoking status when examining this association.

查看原文本刊更多论文

成纤维细胞生长因子19与抑郁症状的关系：吸烟的调节作用

目的：本研究旨在通过BDI评分检测FGF19与抑郁症状之间的关系，并探讨吸烟的调节作用。方法：研究对象为2014年9月至2016年1月的156名中国成年男性（吸烟者78人，非吸烟者78人）。使用BDI评分评估抑郁症状的严重程度。采用Spearman秩相关分析探讨脑脊液FGF19水平与BDI评分的关系。此外，还采用了适度分析和简单斜率分析来评估吸烟对两者关系的调节作用。结果：FGF19水平与所有参与者的BDI评分显著相关（r = 0.26, p < 0.001）。吸烟者脑脊液FGF19水平和BDI评分高于非吸烟者(445.9±272.7 pg/ml vs 229.6±162.7 pg/ml, p < 0.001；2.7±3.0 vs 1.3±2.4,p < 0.001)。脑脊液FGF19水平与非吸烟者BDI评分呈正相关（r = 0.27, p = 0.015），但在吸烟者中未发现类似的关联（r = -0.11, p = 0.32）。线性回归显示FGF19与BDI评分呈正相关（β = 0.173, t = 2.161, 95% CI: 0.015 ~ 0.331, p < 0.05），吸烟对FGF19评分有负相关（β = -0.873, t = -4.644, 95% CI: -1.244 ~ -0.501, p < 0.001）。结论：这些结果强调了FGF19在有抑郁症状存在或进一步发展风险的个体中的潜在作用，并强调了在检查这种关联时考虑吸烟状况的重要性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Acta Neuropsychiatrica NEUROSCIENCES-PSYCHIATRY

自引率

5.30%

发文量

期刊介绍： Acta Neuropsychiatrica is an international journal focussing on translational neuropsychiatry. It publishes high-quality original research papers and reviews. The Journal''s scope specifically highlights the pathway from discovery to clinical applications, healthcare and global health that can be viewed broadly as the spectrum of work that marks the pathway from discovery to global health.